Chiesi Usa Patent-Cliff Exposure & CMS Drug Spending Portfolio
Chiesi Usa (US): 11 reconciled FDA prescription therapies (41.2% 2025 to 2030 cliff risk), $258.0M 2024 CMS Part D & Medicaid spend, and 21 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | US |
| Reconciled FDA Portfolio Therapies | 11 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 41.2% |
| Primary Portfolio LOE Date | 2027-01-01 |
| 2024 CMS Total Public Spend | $258.0M |
| 2024 Medicare Part D Spend | $80.4M |
| 2024 Medicaid Spend | $177.6M |
| California HCAI SB 17 Filings | 21 WAC filings (max 22.5% 2-yr change) |